TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice
TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…